HR | 95% CI | p value | |
---|---|---|---|
Demographics | |||
Age | 1.01 | (1.0–1.02) | 0.20 |
Female sex | 0.72 | (0.53–0.98) | 0.03 |
Dependent living | 1.03 | (0.85–1.24) | 0.77 |
Clinical Characteristics | |||
NYHA class | |||
I/II | reference | ||
III | 1.00 | (0.82–1.21) | 0.96 |
IV | 1.43 | (1.07–1.91) | 0.02 |
Frailty | 1.07 | (0.76–1.50) | 0.69 |
Cardiac comorbidities and interventions | |||
Atrial fibrillation | 1.34 | (1.08–1.66) | 0.01 |
Prior heart failure | 1.08 | (0.81–1.43) | 0.60 |
Prior myocardial infarction | 0.98 | (0.78–1.22) | 0.84 |
PCI | 1.18 | (0.92–1.52) | 0.20 |
CABG | 0.90 | (0.70–1.15) | 0.41 |
Medical comorbidities | |||
Diabetes | 1.05 | (0.86–1.29) | 0.65 |
Cerebrovascular disease | 0.82 | (0.56–1.18) | 0.28 |
Peripheral vascular disease | 1.18 | (1.02–1.37) | 0.02 |
Dementia | 1.22 | (0.69–2.15) | 0.50 |
Dialysis | 1.67 | (1.06–2.65) | 0.03 |
Lung disease | 1.23 | (0.91–1.66) | 0.18 |
Liver disease | 2.00 | (0.63–6.37) | 0.24 |
Peptic ulcer disease | 1.52 | (1.09–2.12) | 0.01 |
History of bleeding | 1.10 | (0.81–1.51) | 0.54 |
Laboratory markers | |||
eGFR | 1.00 | (0.99–1.0) | 0.36 |
Hemoglobin | 0.99 | (0.99–1.0) | < 0.001 |
Echocardiographic findings | |||
Left ventricular dysfunction | 0.73 | (0.54–0.98) | 0.04 |
Procedural characteristics | |||
Urgent procedure | 0.98 | (0.58–1.65) | 0.94 |
Valve in valve | 0.65 | (0.48–0.87) | 0.004 |
Self-expandable prosthesis | 0.98 | (0.84–1.14) | 0.76 |
Non-femoral vascular access site | 1.40 | (1.08–1.81) | 0.01 |
TAVR year | 0.97 | (0.92–1.03) | 0.31 |
Procedural complications | |||
Stroke | 1.09 | (0.82–1.45) | 0.56 |
Permanent pacemaker | 1.21 | (0.83–1.77) | 0.31 |
Delirium | 1.24 | (0.83–1.85) | 0.29 |
Bleeding, vascular complication or transfusion | 1.33 | (1.18–1.50) | < 0.001 |
Echocardiographic findings post-TAVR | |||
Mitral regurgitation | |||
Nil/trace | reference | ||
Mild | 1.23 | (1.10–1.38) | < 0.001 |
Moderate/Severe | 1.26 | (1.03–1.54) | 0.03 |
Aortic regurgitation | |||
Nil/trace | reference | ||
Mild | 1.21 | (0.97–1.52) | 0.10 |
Moderate/Severe | 1.13 | (0.75–1.70) | 0.57 |
Previous health resource utilization | |||
Hospitalization 30 days before TAVR | 1.05 | (0.92–1.20) | 0.48 |
Transitional care factors | |||
Rehabilitation | 1.34 | (1.11–1.62) | 0.002 |
Home care | 1.18 | (0.96–1.44) | 0.12 |
Family physician follow-up | 1.04 | (0.85–1.28) | 0.71 |
Cardiologist follow-up | 1.41 | (1.14–1.75) | 0.002 |